Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 163   

Articles published

NVS 85.84 -0.11 (-0.13%)
price chart
Novartis AG (ADR) (NVS) Stock Update: September Begins With Multiple Deals And ...
Novartis AG (ADR) (NYSE:NVS) has seen an eventful first week of September. The company struck a partnership deal with biotech giant Amgen, Inc. (NASDAQ:AMGN) and won regulatory approvals for several drugs in both the US and Europe - all during the ...
Novartis AG (ADR) On Collision Course With Amgen, Inc. Again With Another ...
Novartis AG ADR (NYSE:NVS) and Amgen Inc. (NASDAQ:AMGN) seem to be on a collision course again as Novartis is on track to get another biosimilar candidate approved by the US Food and Drug Administration (FDA).
Amgen, Inc. Fails To Block Novartis AG (ADR) From Launching Biosimilar
A federal appeals court on Wednesday rejected Amgen Inc.'s (NASDAQ:AMGN) request for a temporary injunction to block Novartis AG (ADR) (NYSE:NVS) from launching a biosimilar version of Amgen's blockbuster drug, Neupogen, in the US. According to ...
Novartis to sell copy of Amgen's Neupogen in US  MarketWatch
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S.
Novartis AG (ADR) (NVS) Stock Update: Decline Driven By Forex Headwinds
Novartis AG (ADR) (NYSE:NVS) stock has registered a decline of 6.06% over the past three months, aided in large part by the global market chaos that's bogging down the entire healthcare sector's stock performance.
Novartis AG (ADR) (NVS) To Acquire Spinifex
Novartis AG (ADR) (NYSE:NVS) has announced the acquisition of Spinifex Pharmaceuticals, Inc. The acquisition will allow Novartis to gain access to Spinifex's experimental drugs for chronic pain.
Novartis AG (ADR) (NVS) To Acquire Spinifex For $200 Million  Bidness ETC
Novartis to buy privately held Spinifex for $200 mln  Proactive Investors USA & Canada
Novartis AG (ADR) Declines As Merck andamp; Co., Wins Patent Battle
Novartis AG ADR (NYSE:NVS) declined 2.3% during yesterday's trade as the company lost a patent battle to Merck & Co.
Novartis AG (ADR) Partners With Amgen, Inc. On Alzheimer's And Migraine
Amgen, Inc. (NASDAQ:AMGN) entered into a two-way partnership deal with Novartis AG (ADR) (NYSE:NVS) on Tuesday, to co-develop the Swiss drug-maker's Alzheimer's drug pipeline, in exchange for Novartis gaining access to Amgen's migraine drug ...
Amgen, Novartis Team Up; Bone Drug Positive in Phase III
Novartis AG (ADR) (NYSE:NVS) Revolade Gets EU Nod
Novartis AG (ADR) (NYSE:NVS) the oncology drug maker is now all set to market key Severe Aplastic Anemia (SAA) drug, Revolade in Europe soon.
GlaxoSmithKline plc (ADR) And Novartis AG (ADR) Complete Three-Part Deal To ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) and Novartis AG (ADR) (NYSE:NVS) announced on Monday that the two companies have completed a series of complicated asset swaps worth $20 billion, in what appears to be a move to tidy up asset portfolios to ...
Asset Swaps Of Novartis AG (ADR) (NYSE:NVS) and GlaxoSmithKline plc (ADR ...
Will Novartis AG (ADR) Buy Pfizer Inc. Biosimilar Remicade?
Pfizer Inc. (NYSE:PFE) nears the completion of its $16 billion acquisition of Hospira Inc. (NYSE:HSP). The deal, which was agreed upon by the two parties in February, secured approval from the European regulators earlier this week, and now awaits ...